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ABSTRAK 
KAJIAN MEN GENAl KESAN UBAT ROSIGLITAZONE KE ATAS INDEKS 
TEKANAN DARAH BUKU LALI-BRAKIAL DI KALANGAN PESAKIT 
DIABETIS MELLITUS JENIS 2 YANG MENJALANI RAW AT AN DI HOSPITAL 
UNIVERSITI SAINS MALAYSIA 
Latarbelakang Rosiglitazone adalah salah satu jenis agen pengurangan gula dari 
kumpulan thiazolidinedione yang digunakan dalam rawatan diabetis mellitus jenis 2. 
Kajian telah menunjukkan ubat ini, yang merupakan agonis penambah peroksisom 
reseptor-gamma mempunyai kesan selain dari pengawalan paras gula. Selain dari 
memperbaiki rintangan terhadap insulin, contoh-contoh kesan rosiglitazone yang tidak 
berkaitan dengan pengurangan gula adalah pengurangan penanda aras keradangan, 
memperbaiki fungsi endotelial, memperbaiki aktiviti fibrinolitik dan perubahan dalam 
profil kolesterol. Kajian ini ingin memperlihatkan secara klinikal kesan pengurangan 
aterosklerosis serta penambahbaikan sistem fibrinolitik selepas penggunaan rosiglitazone. 
Objektif kajian ini adalah untuk menilai perubahan secara tidak langsung beban 
aterosklerosis dengan mengukur indeks tekanan darah buku lali-brakial, bilangan pesakit 
di dalam kajian ini yang mempunyai penyakit arteri yang signifikan, perubahan dalam 
sifat kecenderungan untuk salur darah tersumhat di kalangan pesakit kencing manis 
dengan mengukur tahap aktiviti plasminogen dalam serum, perubahan kawalan paras 
gula dengan mengukur HbAtc dan perubahan dalam profil kolesterol dengan mengukur 
kolesterol keseluruhan, lipoprotin kolesterol berketumpatan tinggi serta lipoprotin 
kolesterol berketumpatan rendah setelah rosiglitazone ditambah ke regim rawatan 
kencing manis jenis ke-2. 
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Kaedah Sebuab kajian kohort hirisan lintang direka di mana pesakit serta doktor 
tabu akan jenis ubat yang diberi. 59 pesakit telah diambil untuk kajian. Pesakit yang 
belurn pemah menggunakan rosiglitazone diberikan 4mg untuk dimakan selama 10 
minggu. Ubat ini ditambah kepada ubatan pesakit yang sedia ada. Indeks tekanan darah 
buku lali-brakial, HbA1c, paras aktiviti serum plasminogen serta profil kolesteroI 
(berpuasa) diambil pada permulaan dan akhir tempoh kajian. Pesakit diminta tidak 
menukar dos serta regimen ubat-ubatan mereka ketika tempoh kajian. 
Kepulusan Seramai 48 daripada 59 pesakit dinilai pada akhir tempoh kajian. Purata 
indeks tekanan darah buku lali-brakial adalah 1.06 ± 0.12 sebelum dan 1.07 ± 0.13 
selepas rosiglitazone ditambah (p=0.439). Seramai 4 pesakit (8.3%) mempunyai nilai 
indeks tekanan darah buku lali-brakial kurang <0.90. Purata aktiviti serum 
plasminogen(%) adalah 96.00 ± 14.77 sebelum rosiglitazone, dan 111.98 ± 15.83 selepas 
(p=0.006). HbAlc (0/0) pada permulaan kajian adalah 9.76 ± 2.06, dan purata selepas 
kajian 9.25 ± 2.03 (p<0.001). Purata kolesterol keseluruhan (mmollL) adalah 4.95 ± 1.02 
sebelum rosiglitazone dan 5.32 ± 0.94 selepas (p=0.003). Purata lipoprotin kolesterol 
berketurnpatan tinggi (mmol/L) pada permulaan kajian adalah 1.32 ± 0.37 dan 1.47 ± 
0.41 di penghujung, p<O.OO 1. Selain dari itu, purata lipoprotin kolesterol berketumpatan 
rendah (mmoIlL) adalah 2.89 ± 0.85 pada awal kajian dan 3.08 ± 0.96 di akhir kajian 
(p=0.098). 
Kesimpu/an Kajian ini menunjukkan rosiglitazone 4mg yang dimakan sekali sehari 
memperbaiki tahap aktiviti serum plasminogen. Ini mungkin menandakan aktiviti 
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fibrinolitik rnakin berkesan. Kajian ini walaubagaimanapun tidak dapat menentukan 
kesannya secara klinikal. HbA I c juga berkurangan secara signifikan. Selain dari ini, 
terdapat pertambahan jumlah kolesterol keseluruhan serta tahap lipoprotin kolesterol 
berketumpatan tinggi sarna seperti kajian lain sebelum ini. Pertarnbahan indeks tekanan 
darah buku lali-brakial serta tahap lipoprotin kolesterol berketurnpatan rendah tidak 
signifikan dalarn kaj ian ini. Bilangan pesakit yang mernpunyai penyakit arteri yang 
signifikan tidak rarnai dalam kajian ini berbanding kajian lain yang dijalankan sebelum 
ini. Kajian yang lebih Ianjut diperlukan untuk menunjukkan perkaitan antara penggunaan 
rosiglitazone dan pengurangan aterorna. 
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ABSTRACT 
A STUDY ON THE EFFECT OF ADD-ON ROSIGLITAZONE ON THE ANKLE-
BRACmAL PRESSURE INDEX OF PATIENTS WITH TYPE 2 DIABETES 
MELLITUS IN HOSPITAL UNIVERSITI SAINS MALA YSIA 
Background Rosiglitazone, an oral hypoglycaemic agent of the thiazolidinedione group 
is used for Type 2 Diabetes treatment. Research has shown that this medication, being a 
peroxisome proliferator activator receptor-gamma agonist has effects beyond glycaemic 
control alone. Apart from improving insulin resistance, the non-hypoglycaemic effects of 
rosiglitazone include reduction of inflammatory markers, improvement of endothelial 
function, improvement in fibrinolytic activity as well as changes in cholesterol profile. 
This study intends to see if the non-hypoglycaemic effects of rosiglitazone translate to a 
clinically noticable reduction in atherosclerosis as well as improvement of fibrinolytic 
activity. The objectives of this study were to assess changes in surrogate markers of 
atherosclerotic burden via ankle-brachial pressure index measurements, the number of 
patients who have significant peripheral artery disease in the study, changes in the 
diabetic prothrombotic state via serum plasminogen activity, changes in glycaemic 
control via HbAlc and changes in cholesterol profile by measuring total-, high density 
lipoprotein- and low density lipoprotein-cholesterol after rosiglitazone is added to a pre-
existing Type 2 Diabetes treatment regime. 
Methods A non-blinded cross-sectional cohort study was designed. 59 patients were 
enrolled. Patients who were rosiglitazone naive were prescribed 4mg of oral rosiglitazone 
added-on to their current medication for a period of 10 weeks. Ankle-brachial pressure 
index, HbAlc, serum plasminogen activity levels and fasting cholesterol profile were 
xiv 
taken at the start and end of the study period. Patients were requested not to change their 
medication dose nor regime throughout the study. 
Results 48 out of 59 patients completed the study. Mean ankle-brachial pressure 
index was 1.06 ± 0.12 pre-, and 1.07 ± 0.13 post-rosiglitazone (p-value was 0.439). 4 
patients (8.3%) had an ABPI ratio of less than 0.90 indicating presence of significant 
peripheral artery disease. Mean serum plasminogen activity (%) was 96.00 ± 14.77 
before rosiglitazone, and 111.98 ± 15.83 after (p-value of 0.006). Initial mean HbAlc (%) 
was 9.76 ± 2.06, and second mean was 9.25 ± 2.03 (p-value was <0.001). Mean total 
cholesterol (mmoI/L) was 4.95 ± 1.02 before rosiglitazone and 5.32 ± 0.94 after 
(p=0.003). Mean high density lipoprotein cholesterol (mmollL) at the beginning was 1.32 
± 0.37 and 1.47 ± 0.41 at the end (p<O.OOl). Finally, mean low density lipoprotein 
cholesterol (mmoI/L) concentration was 2.89 ± 0.85 at the start and 3.08 ± 0.96 at the end 
(p= 0.098). 
Conclusion This study shows that oral rosiglitazone 4mg daily significantly improves 
serum plasminogen activity levels, indicating improvement in fibrinolytic activity. There 
is also a significant reduction in HbAlc, rise in total cholesterol as well as high density 
lipoprotein-cholesterol levels in line with the findings of previous studies. The rise in 
ankle-brachial pressure index and low density lipoprotein-cholesterol measurements 
however, were not significant in this study. Not many patients had significant peripheral 
artery disease in this study compared to previous ones before this. However, more 
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1.1 Background and Epidemiology 
Tbt' first ever recorded case of diabetes was by the 3rd Dynasty Egyptian physician Hesy-
Ra in 1- "52 (Shampo et aI, 1981). Since then, much has been learnt regarding this disease: 
its patho physiology, the types of persons affected, the natural history of the different 
types of diabetes as well as the complications associated with it, to name a few. 
Ac cording to the World Health Organisation (WHO) Fact Sheet on Diabetes Mellitus, 
patients can generally be divided into 3 groups: those that have Type I Diabetes Mellitus 
(which o ccurs due to lack of insulin production), Type 2 Diabetes Mellitus patients (those 
having innpaired insulin secretion and/or peripheral insulin resistance) as well as diabetes 
wh ich p resents in pregnancy, termed Gestational Diabetes Mellitus. The American 
Di afuetes Association also recognises secondary diabetes, ie diabetes mellitus which is 
du e to another underlying pathology eg haemochromatosis or Cushing' s syndrome. 
Th t' WHO estimates that currently more than 180 million people worldwide have 
diabetes., and this number is likely to more than double by 2030. An estimated 1.1 million 
pe ople died from complications related to diabetes in 2005. Initially thought to be a 
disease affl icting affluent nations, it has been shown that almost 80% of diabetes deaths 
occur in low and middle-income countries. Having said this however, diabetes deaths are 
projected to increase by over 80% in upper-middle income countries between 2006 and 
2015 (WHO Fact Sheet, 2006). The majority of patients are Type 2 diabetics and thus 
efforts are targeted towards reducing the incidence of new cases as well as associated 
IlliOlbidiity and mortal ity. In Malaysia, the prevalence of diabetes was estimated to be 
0.65% in 1960, 2.1 % in 1982, and 6.3% in 1986. This increased to 8.3% in 1996 
(Mustaffa, 1990; Second National Health and Morbidity Survey, 1997; Zaini, 2000). A 
study by Mafauzy et al in 1999 though showed that the prevalence of diabetes in the 
Peninsular Malaysia North-Eastern state of Kelantan to be as high as 10.5%. Apart from 
this the subjects studied also had a high prevalence of obesity, hypertension and 
hypercholesterolaemia (Mafauzy et aI, 1999). 
1.2 Pathophysiology of Type 2 Diabetes Mellitus 
Type 2 Diabetic patients by far comprise the largest group at more than 90% of overall 
diabetic patients. The progress of this disease is relentless; it advances from an early 
asymptomatic stage with insulin resistance to mild postprandial hyperglycaemia and 
finally full blown diabetes requiring pharmacological intervention. Three basic metabolic 
defects define Type 2 Diabetes Mellitus: insulin resistance, a non-autoimmune pancreatic 
~-cell insulin secretory defect, as well as increased hepatic gluconeogenesis. The cause of 
these metabolic defects, and therefore the cause of Type 2 Diabetes Mellitus, is largely 
unknown. It has been shown though to have a strong genetic component and is found 
more frequently in certain families and ethnic minority groups. Many acquired factors 
also playa role in the pathogenesis of the disease. Factors that contribute to insulin 
resistance include obesity, aging, and a sedentary lifestyle. Other contributing factors to 
the insulin secretory deficiency include long-term glucotoxicity and elevated free fatty 
acid levels. 
The metabolic sequence of events that eventually lead to type 2 diabetes herald the 
development of hyperglycaemia by years or even decades. Insulin resistance is the initial 
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metabolic defect and as it worsens, more defects in insulin secretion occur that result in 
increased hepatic glucose production. At this point, there is a further rise in fasting blood 
glucose (termed "impaired fasting glucose"- IFO). This worsens later on, leading to 
impaired glucose tolerance - lOT. The progression from lOT to early type 2 diabetes is 
marked by a decrease in ~-cell function and thus a further decline in insulin secretion. It 
is the gradual pancreatic ~-cell failure to compensate for insulin resistance as well as 
hyperinsulinaemia that precedes the development of Type 2 Diabetes. Two more 
pathophysiological changes become apparent during the transition from lOT to type 2 
diabetes: 1) insulin resistance becomes more severe due to the factors mentioned above, 
and 2) there is a concomittant increase in baseline hepatic glucose production. Though 
early Type 2 diabetes may be as asymptomatic as lOT, the degree of hyperglycaemia is 
now severe enough for the development of microvascular complications. Apart from this, 
lOT and insulin resistance are associated with low levels of HDL cholesterol, increases in 
triglycerides, and hypertension. These metabolic problems, in combination with changes 
in factors involved in the coagulation cascade, may result in accelerated atherosclerosis 
and early macrovascular complications (Ramlo-Halsted et aI, 2000). 
1.3 Treatment of Type 2 Diabetes Mellitus 
Thus, in an effort to reduce cardiovascular-associated mortality treatment goals are 
directed at improvement of classical cardiovascular risk factors eg optimal control of 
glycaemia, hyperlipidaemia (namely LDL-C), and blood pressure according to 
guidelines. Treatment essentially can be divided into two groups, ie non-pharmacological 
interventions which include lifestyle changes eg cessation of smoking, proper diet control 
and exercise. Pharmacological interventions eg oral hypoglycaemic agents or insulin 
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injections may also be required; these will be elaborated on in later paragraphs. 
According to the International Diabetes Federation (IDF) Western Pacific Region 
guidelines regarding control of diabetes, the optimal fasting plasma glucose level should 
be between 4.4-6.1 mmollL, optimal non-fasting plasma glucose level of 4.4-S.0mmoI/L 
and optimal HbA1c of less than 6.5% (Asian-Pacific Type 2 Diabetes Policy Group, 
2002). 
Apart from the lifestyle modifications mentioned above, there are many classes of oral 
hypoglycaemic agents (OHAs) available for the pharmacological treatment of Type 2 
diabetes. There is metformin, a biguanide which suppresses hepatic gluconeogenesis and 
increases peripheral insulin sensitivity. It is usually used as a first-line agent in obese 
patients as it promotes peripheral glucose uptake and also has an appetite suppressing 
effect. Secondly, there is the sulphonylurea group of OHAs. These act as insulin 
secretagogues; they may be used as first-line agents in non-obese Type 2 diabetics or as 
add-on therapy. Thirdly are the meglitinides. These are also insulin secretagogues, but 
have a shorter duration of effect than sulphonylureas. Meglitinides are better suited to 
address the issue of post-prandial hyperglycaemia. Fourthly are the thiazolidinediones. 
These drugs are peroxisome proliferator-activated receptor-gamma agonists which 
amongst other effects, acts as an insulin sensitiser. Then there are the a-glucosidase 
inhibitors which reduce glucose absorption at the intestinal brush border. 
Patients who fail to achieve glycaemic targets using OHAs should be considered for 
insulin therapy. Insulin itself comes in many preparations; from the ultra-short acting 
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ones up to insulins with 24-hour duration of action. A combination of OHAs and 
subcutaneous insulin injections may also be considered depending on the situation. An 
inhalable insulin preparation is also available commercially (Hite et aI, 2006). 
A new drug which has entered the market is exenatide, an incretin mimetic which 
promotes pancreatic insulin secretion. It comes in the form of an subcutaneous injection 
administered twice a day. It has been approved for adjuvant, as well as monotherapy in 
Type 2 diabetics. 
The International Diabetes Federation has also produced Global Guidelines for the 
treatment of Type 2 Diabetes Mellitus. Recommendations are divided into 
comprehensive, standard and minimal care. With standard care, a patient is started on 
OHAs when lifestyle interventions alone are unable to maintain target glycaemic control. 
Support for lifestyle measures are maintained throughout the periods of use of oral 
medications. 
The glycaemic response is monitored every 2-6 months via FBS, RBS or HbAlc. If 
targets are not achieved, it should be considered whether to increase the dose of the oral 
agent or to initiate another. Patients ought to be started with metformin unless there is 
evidence or risk of renal impairment, titrating the dose over several weeks to minimise 
discontinuation due to gastro-intestinal upset. The renal function should also be regularly 
monitored. The next step is to use sulfonylureas when metformin fails to control glucose 
concentrations to target levels, or as a first-line option in the non-overweight person. A 
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low-cost drug should be considered first before initiating more expensive ones, unless the 
situation warrants differently. 
Education needs to be provided and, if appropriate, self-monitoring to guard against the 
consequences of hypoglycaemia. If compliance is an issue, once-daily sulfonylureas 
should be an available option. In patients who may not have regular meals due to a hectic 
schedule for example, the rapid-acting insulin secretagogues (eg meglitinide group of 
ORAs) may be useful compared to sulfonylureas. However, this may only work if the 
patient can still produce insulin and has good insulin sensitivity. PPAR-,), agonists 
(thiazolidinediones) are used when glucose concentrations are not at target levels, adding 
it: a) to metformin as an alternative to a sulfonylurea, or b) to a sulfonylurea where 
metformin is not tolerated, or c) to the combination of metformin and a sulfonylurea. In 
such cases the patient should be screened for cardiac failure, as this is a contra-indication 
for the use of thiazolidinediones, and the patient should be warned of the possibility of 
developing significant peripheral oedema. Failing these steps, a-glucosidase inhibitors 
can be used as a further option. These may also have a role in patients who do not tolerate 
other therapies. Doses are increased stepwise, and other oral glucose-lowering drugs are 
added one by one until blood glucose control is at target levels. All along, the patient 
should be monitored for deteriorating glycaemic control despite these measures; the 
patient may need early insulin therapy if OHAs fail to adequately control blood sugar 
levels (Clinical Guidelines Task Force, 2005). 
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1.3.1 Thiazolidinediones 
It has been increasingly shown however that a specific pharmacological intervention can 
also confer benefit beyond its initial scope of use. An example of this would be the use of 
statins which have been shown to reduce vascular inflammatory markers as well as 
improve plaque stability, an effect beyond just LDL-c reduction alone (Kinlay et aI, 
2003). Amongst the plethora of oral hypoglycaemic agents which are available though, 
more evidence is emerging to show that rosiglitazone (Avandia®, Glaxo-SmithKline) has 
effects other than reduction of blood glucose levels eg improvement in fibrinolysis, 
reduction in inflammatory markers as well as reduction in blood pressure and 
atherosclerotic plaque (Haffner et ai, 2002; Mohanty et aI, 2001; Law et al 2000; 
RECORD study preliminary report, due 2008; Raji et ai, 2003). 
Rosiglitazone is a member of the thiazolidinedione class of antidiabetic agents which 
improves glycaemic control by improving insulin sensitivity. It is a highly selective and 
potent agonist for the peroxisome proliferator-activated receptor-gamma (PPAR-,),). In 
humans, PP AR receptors are found in key target tissues for insulin action such as adipose 
tissue, skeletal muscle, and liver. Activation of PPAR-,), nuclear receptors regulates the 
transcription of insulin-responsive genes involved in the control of glucose production, 
transport, and utilisation. In addition, PP AR-,), responsive genes also participate in the 
regulation of fatty acid metabolism (A vandia product monograph, 2006). With regards to 
insulin sensitivity and secretion, the thiazolidinediones have been proven to lower fasting 
and postprandial glucose concentrations as well as free fatty acid concentrations in 
clinical studies. Studies also showed that insulin concentrations were also reduced, 
7 
indicating that thiazolidinediones act as insulin sensitisers. This has been confirmed by 
direct measurements in human subjects. Nondiabetic subjects or those with Type 2 
Diabetes were treated for three to six months with troglitazone, rosiglitazone, or 
pioglitazone. This increased their insulin-stimulated glucose uptake in peripheral tissues. 
Other similar studies showed that thiazolidinediones increased hepatic insulin sensitivity 
(ie the ability of insulin to reduce endogenous glucose production) and insulin sensitivity 
in adipose tissue (measured from the ability of insulin to suppress free fatty acid 
concentrations). This improvement in insulin secretory responses were also shown to be 
present in subjects with impaired glucose tolerance and Type 2 Diabetes Mellitus, even 
after being adjusted for an improvement in insulin sensitivity. An unwanted side-effect 
though is that these improvements are generally accompanied by weight gain and an 
increase in the subcutaneous adipose-tissue mass. 
At the cellular level, PPAR-1 is needed for normal adipocyte differentiation and 
proliferation as well as fatty acid uptake and storage. What thiazolidinediones do is that 
they increase the number of small adipocytes and the subcutaneous adipose-tissue mass 
in studies in animal models. Due to this as well as the high level ofPPAR-"r expression in 
adipose tissues, have led to the hypothesis that thiazolidinediones exert their insulin-
sensitising actions either directly (the "fatty acid steal" hypothesis) or indirectly, by 
means of altered adipokine release, thus modulating insulin sensitivity outside adipose 
tissue. The "fatty acid steal" hypothesis describes thiazolidinediones as promoting fatty 
acid uptake and storage in adipose tissue and thus increasing adipose-tissue mass and 
protects other insulin-sensitive tissues eg skeletal muscle and the liver, and possibly 
8 
